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THE HLA SYSTEM
HLA-A, B, C (CLASS I) ANTIGENS
Immunogenetic Studies With In Vitro Generated
Cytotoxic Lymphocytes of Cell-Mediated Lympholysis
(CML) Nonreactive Kidney Graft Recipients
E. Goulmy, E. Blokland, G. G. Persijn, and J. J. van Rood
ONE of the cellular test Systems which, atthe moment, can be used as an in vitro
refiection of the in vivo homograft reaction is
the cell-mediated lympholysis (CML) tech-
nique. The development of donor-specific
CMI nonreactivity (CML-NR) in recipients
of HLA-nonidentical related and unrelated
donor kidneys has been documented in several
reports.1 3 Our studies, containing 82 unre-
lated donor/recipient combinations, showed
that the development of donor-spccific CML-
NR correlated significantly with good kidney
graft function. Furthermore, donor-specific
CML-NR occurred more frequently in those
donor/recipient combinations that were
matched for (A) the HLA-B locus antigens
and (B) male sex.4 Additionally, we observed
that donor-specific CML-NR could not be
abolished by pool Stimulation of the recip-
ients' lymphocytes,5 i.e., after Stimulation of
the CML-NR recipients' lymphocytes to-
wards a pool of randomly selected stimulator
cclls, no cytolytic activity against the specific
kidney donor splenocytes could be observed.
Howcver, despite a normal CML reactivity
against conirol and pooled cells as target cells>,
absencc of cytolytic activity after pool Stimu-
lation was observed not only against the spe-
cific kidney donor splenocytes as target cells,
but also against some individual target cells
from the pool. The latter CML-NR seemed to
be influenced by the HLA match of the indi-
vidual target cells from the pool.5
In an attempt to clarify this pattern of
cytolytic nonreactivity, we subsequently slud-
ied the cytolytic capacity of the CML-NR
patients' lymphocytes against a selected pane!
of unrelated blood donors as specific stimula-
tor cells, e.q., target cells. Absence of CML-
NR was not only observed against the specific
kidney donor splenocytes, but also against
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several unrelated blood donors. These donors
shared the HLA-B or HLA-B and C anügens
with the specific kidney donors. Our results
indicate so far that the occurrence of kidney-
donor-specific CML-NR against unrelated
blood donors as stimulator cells depends on
the kidney donor Η LA-Α and C antigens.
MATERIALS AND METHODS
Donor-specific CML-NR occurred in 70% of 82
patients with a funclioning graft Immunogeneüc studies
were peiformed with the lymphocytes of 16 CML non-
reactive patients
Protocol immunogenetic studies Lymphocytes of
CML nonreactive patients (posttransplantation) were
stimulated in vitro against (1) specific kidney donor
splenocytes, (2) HLA-A, B, C, and DR incompatible
control cells, and (3) selected stimulator cells from unre-
lated blood donors that differed from the kidney donor for
HLA-A antigens, HLA-B antigens, HLA-C antigens,
and (4) combinations thereof
CML techruque The Standard CML assay has been
desenbed before in detail "
RESULTS
The results of immunogenetic studies with
lymphocytes of an CML-NR patient are
shown in Table 1. CML reactivity was
observed against HLA-incompatible control
cells and against specific stimulator/target
cells 1,3, 4, and 5. Absence of CML reactivity
was observed, as expected, against the specific
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kidney donor splenocytes and in addition
against stimulator/target cells 2. It is remark-
able that stimulator/target cells 2 carried the
same HLA-B and C antigens as the original
specific kidney donor.
To control the percentages of specific lysis
obtained by patients' lymphocytes, responder
cells that were HLA identical to the patient
were stimulated following the same protocol,
and subsequently tested against the same spe-
cific target cells. Positive lysis could be shown,
without any exception, against all target
cells.
Table 2 shows the CML pattern of 5 dif-
ferent patients stimulated and tested against
specific kidney donor splenocytes; HLA-
incompatible control cells and 7 selected
stimulator/target cells differing either for
HLA-A antigens, HLA-B antigens, HLA-C
antigens, or combinations thereof The
responder cells of the 5 patients all showed
positive lysis against HLA-incompatible con-
trol cells, target cells 5, 6, and 7, and in 3 of 5
cases, against target cells 4. CML-NR was
observed not only against the specific kidney
donor splenocytes, but also against target cells
1, 2, and 3, and in 2 of 5 cases against target
cells 4. The most striking similarity between
stimulator/target cells 1, 2, 3, and 4 is that
Table 1 Immunogenetics of CML Nonreactivity
Responder
Cells
Rt
X
Donorf
-I 10*
4 22
Control
^ 39
+ 69
A ^
B-
DR^
1
^ 37
-i 65
Stimulator/Target Cells
A ^
Β
C #
DR 5*
2
^ 8
f 4 7
C-
D R ^
3
Λ 19
+ 66
Α
C-
DR-
4
I 28
Η 26
A~
B ^
C
DRi*
5
+ 64
+ 58
* Percent specific lysis
f HLA phenotypes (responder stimulator/target cells) kidney donor—A1 A3, Bw35 B37 Cw6DR1 5, recipient—A1
Aw19, B17 B37,Cw3DR1
X, HLA identical to the patient
Control cells A1.A2 B8 Bw44 Cw5 DR3, 4
Stim /target cells 1 A3, Aw32 Bw35 Cw4DR1 8
Stirn /target cells 2 A3, A9 Bw35 B37 Cw6 DR4
Stirn/target cells 3 A3, A26, B7 Β 13 Cw6 DR1 2
Stirn/target cells 4 A1.A3, Bw35 B40 Cw2, 4, Dr1
Stim /target cells 5 A1 A3 B8, B17Cw6DR3
Posttransplant patients lymphocytes and lymphocytes from X were sensitized in vitro against different stimulator cells (see
Materials and Methods) and thereafter tested in CML against the specific target cells
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Table 2 Immunogenetics of CML Nonreactivity
Responder
Cells*
Stimutator/Target Cells
Donor
A -
B
Control 1
A -
B -
A -
C
5
C-
7
1
2
3
4
5
+ 4f
+ 1
4 3
+ 3
1
^ 51
+ 36
+ 27
4 83
+ 43
+ 1
1
-1 7
h8
1
- 1
-14
+ 1
„ f
h2
+ 4
2
Η 20
+ 38
+ 1
+ 6
4 22
4 56
+ 65
+ 21
t-48
+ 43
+ 72
+ 47
+ 48
+ 56
Η 31
4 37
+ 42
+ 54
Η 68
*Responder cells 1 -5 represent lymphocyte populations of 5 different patients posttransplantation
fPercent specific lysis
Patients lymphocytes were sensitized in vitro against different stimulator cells (see Materials and Methods) and thereafter
tested in CML against the specific target cells
they carned the same HLA-B (or Β and C)
antigens as the original kidney donor
DISCUSSION
HLA matching does impove graft survival
in unrelated donor/recipient combinations,
and moreover, influences the development of
posttransplant CML-NR We observed that
the occurrence of CML-NR, besides lts sig-
nificant correlation with good graft function,
occurred more frequently in donor/recipient
combinations that were matched for HLA-B
locus antigens4
It was the aim of this immunogenetic study
to define the more precise role of the HLA
System on the occurrence of CML-NR The
results presented in Tables 1 and 2 (which are
representative for 16 patients studied) demon-
strate that donor-specific CML-NR does
occur not only against the specific kidney
donor splenocytes as target cells, but also
against other target cells Immunogenetic
studies show that donor-specific CML-NR
also occurs against the kidney donor-specific
HLA-B or HLA-B and C antigens presented
on lymphocytes of selected unrelated blood
donors as stimulator cells Thus, shanng of
HLA-B or HLA-B and C antigens with the
specific kidney donor causes significantly less
lysis
The possible mechamsms of the occurrence
of CML-NR dgainst donor-specific HLA-B
or HLA-B and C antigens are
(1) HLA-B or HLA-B and C antigens are
the major cytotoxic determinants This would
implicate that HLA-A antigens are poor tar-
gets in CML This seems unlikely, since
alloimmune HLA-A2 CTLs (generated be-
tween unrelated responder/stimulator cell
combinations diffenng only for the HLA-A2
antigen) showed good cytotoxicity 6
(2) Elimination or clonal deletion of spe-
cific anti-donor cytotoxic clones of effector
cells by antudiotypic antibodies Evidence in
this direction has been reported by Miyajima
et al ,7 who showed specific Inhibition of cer-
tain MLR by antudiotypic antibodies in a
patient with a functioning renal graft In
addition, Singal et a l 8 showed that antibodies
directed against recognition Sites on Τ lym-
phocytes can also be induced by blood transfu-
sions In both latter reports, specific anti-
bodies capable of inhibiting prohferative
responses in MLC were directed against
HLA-B antigem of the kidney donor 7 8 This
observation IS very stnking, especially bccause
in our immunogenetic studies, occurrence of
kidney donor-specific CML-NR against unre
lated blood donors as stimulator cells depends
on the kidney donor HLA-B (or HLA-B and
C) antigens
(3) Compatibihty for HLA-B (or HLA-B
and C) between donor and recipient can
induce suppression Liburd,9 Thomas,10 and
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several other authors described the presence
of suppressor cells responsible for the occur-
rence of CML-NR. With Special reference to
the latter studies and our observations, it
seems important to search for the influence of
the Η LA System on the induction of suppres-
sion of the specific anti-donor CML reactivity
posttransplantation.
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